Reversal of pre-existing NGFR-driven tumor and immune therapy resistance.

Boshuizen, Julia; Vredevoogd, David W; Krijgsman, Oscar; Ligtenberg, Maarten A; Blankenstein, Stephanie; de Bruijn, Beaunelle; Frederick, Dennie T; Kenski, Juliana C N; Parren, Mara; Brüggemann, Marieke; Madu, Max F; Rozeman, Elisa A; Song, Ji-Ying; Horlings, Hugo M; Blank, Christian U; van Akkooi, Alexander C J; Flaherty, Keith T; Boland, Genevieve M; Peeper, Daniel S

Boshuizen, Julia; Vredevoogd, David W; Krijgsman, Oscar; Ligtenberg, Maarten A; Blankenstein, Stephanie; de Bruijn, Beaunelle; Frederick, Dennie T; Kenski, Juliana C N; Parren, Mara; Brüggemann, Marieke; Madu, Max F; Rozeman, Elisa A; Song, Ji-Ying; Horlings, Hugo M; Blank, Christian U; van Akkooi, Alexander C J; Flaherty, Keith T; Boland, Genevieve M; Peeper, Daniel S.

Boshuizen J; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Vredevoogd DW; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Krijgsman O; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Ligtenberg MA; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Blankenstein S; Division of Surgical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
de Bruijn B; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Frederick DT; Department of Surgical Oncology, Massachusetts General Hospital, Boston, MA, USA.
Kenski JCN; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Parren M; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Brüggemann M; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Madu MF; Division of Surgical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Rozeman EA; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Song JY; Division of Animal Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Horlings HM; Division of Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Blank CU; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
van Akkooi ACJ; Division of Surgical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Flaherty KT; Department of Medical Oncology, Massachusetts General Hospital, Boston, MA, USA.
Boland GM; Department of Surgical Oncology, Massachusetts General Hospital, Boston, MA, USA.
Peeper DS; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands. d.peeper@nki.nl.

Nat Commun ; 11(1): 3946, 2020 08 07.

Article en En | MEDLINE | ID: mdl-32770055

Asunto(s)

Antineoplásicos Inmunológicos/farmacología; Melanoma/tratamiento farmacológico; Proteínas del Tejido Nervioso/metabolismo; Inhibidores de Proteínas Quinasas/farmacología; Receptores de Factor de Crecimiento Nervioso/metabolismo; Neoplasias Cutáneas/tratamiento farmacológico; Linfocitos T Citotóxicos/inmunología; Animales; Antineoplásicos Inmunológicos/uso terapéutico; Factor Neurotrófico Derivado del Encéfalo/antagonistas & inhibidores; Factor Neurotrófico Derivado del Encéfalo/metabolismo; Línea Celular Tumoral; Resistencia a Antineoplásicos/genética; Femenino; Regulación Neoplásica de la Expresión Génica; Células HEK293; Humanos; Masculino; Melanoma/genética; Melanoma/inmunología; Melanoma/patología; Ratones; Quinasas de Proteína Quinasa Activadas por Mitógenos/antagonistas & inhibidores; Proteínas del Tejido Nervioso/antagonistas & inhibidores; Receptor de Muerte Celular Programada 1/antagonistas & inhibidores; Receptor de Muerte Celular Programada 1/inmunología; Inhibidores de Proteínas Quinasas/uso terapéutico; Proteínas Proto-Oncogénicas B-raf/antagonistas & inhibidores; RNA-Seq; Receptores de Factor de Crecimiento Nervioso/antagonistas & inhibidores; Neoplasias Cutáneas/genética; Neoplasias Cutáneas/inmunología; Neoplasias Cutáneas/patología; Linfocitos T Citotóxicos/metabolismo; Escape del Tumor/genética; Microambiente Tumoral/efectos de los fármacos; Microambiente Tumoral/genética; Microambiente Tumoral/inmunología; Ensayos Antitumor por Modelo de Xenoinjerto

Texto completo

Imprimir

XML

PubMed Links

Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Cutáneas / Linfocitos T Citotóxicos / Receptores de Factor de Crecimiento Nervioso / Inhibidores de Proteínas Quinasas / Antineoplásicos Inmunológicos / Melanoma / Proteínas del Tejido Nervioso Tipo de estudio: Prognostic_studies Idioma: En Año: 2020 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Search on Google